AI for Architectural Planning that allows users to effortlessly generate layout plans and visualizations to further accelerate global adoption; users generate over 400 million square feet in record time
TEL AVIV, Israel, Jan. 15, 2025 /PRNewswire/ — qbiq, the largest and one of the first AI companies focused on automating architectural planning, today announced the closing of a $16 million Series A round led by global software investor Insight Partners. The round included participation from JLL Spark, 10D, Ocean Azul, Random Forest and M-Fund.
qbiq’s software enables non-architects and architect users alike to immediately plan, visualize and optimize any given space. With a simple input of requirements – from seat count to finish materials – qbiq’s AI generates a complete design package including optimized floor plans, 3D visualizations, architectural programs, quantity estimates, Revit/CAD models and more. qbiq transforms complex design processes into easy-to-use solutions that can dramatically accelerate decision-making and transactions for brokers, landlords, tenants, architects, general contractors, and co-working chains.
The investment will drive qbiq’s mission to standardize automated architectural capabilities in commercial real estate, making architectural planning faster, accessible, and more efficient for non-designers and designers alike.
A New Era of Automated Architectural Capabilities
Since launch, qbiq’s customers have created over 400 million square feet of architectural layouts and visualizations in hours, replacing weeks or even months of manual work to accelerate decision-making and reduce deal cycles. The customer base has grown more than tenfold and qbiq continues to see increasing demand.
“When we officially launched in 2023, I discussed reaching 100 million square feet delivered to clients as a KPI. This was thought by many to be unrealistic. By 2024 we had already quadrupled that goal and are now speeding towards the 1 billion square foot mark,” says Leeor Solnik, qbiq’s CEO & Co-Founder. “Joining forces with Insight Partners is a big milestone for qbiq, enabling the acceleration of our global expansion and paving our way towards a real industry transformation.”
Liad Agmon, Managing Director at Insight Partners, led the investment in qbiq and will join the company’s board of directors.
“When I was CEO, we would have at least one major office move per year across our global offices. Understanding whether a vacant space would be optimal for our needs was a tedious and lengthy process that would often take weeks and involve back and forth between our team, landlords, and our architects. I was impressed by how elegantly qbiq solves this problem, saving valuable time and money to all parties involved.” said Agmon. “With qbiq, we’re witnessing a game-changing shift—helping define a new era of automated architectural planning.”
Ending the decades-long dependency on manual architectural workflows
qbiq tackles one of real estate’s biggest pain points: the inefficiency of traditional architectural planning, which leads to delays and prolonged deal cycles.
For decades, creating layouts involved slow, manual work using tools like AutoCAD, with architects solving complex design problems line by line. Even after completing a layout, interpreting it can be challenging—especially for those without a design background. Creating clarity through visuals, such as rendered tours and images, is a costly, months-long process, making it impractical for most deals and projects.
qbiq has created one of the first Architectural AI platforms that allows brokers, landlords, architects, general contractors, and tenants to easily envision the full potential of any space in minutes, while considering basic or complex requirements. Customers such as Brookfield Properties, JLL, Skanska and IWG are able to easily create a wide range of architectural outputs for any space in minutes. These outputs include architectural programs, programmatic or conceptual layouts, high-resolution rendered tours and images, quantity takeoffs CAD/Revit models and more.
About qbiq
qbiq leverages generative AI to automate and democratize architectural planning at any scale. With qbiq, tenants make highly informed decisions, brokers close deals and projects faster, landlords increase ROI from reduced vacancies due to shorter deal cycles and architects can boost their planning capacity. Founded in 2019 by Leeor Solnik, Elad Kaminer, Noam Diamantstein and Roey Granot. qbiq is headquartered in Tel Aviv, with offices in New York and Miami. To date, qbiq has delivered over 400 million square feet of plans, transforming real estate transactions for hundreds of clients globally.
Insight Partners is a global software investor partnering with high-growth technology, software, and Internet startup and ScaleUp companies that are driving transformative change in their industries. As of June 30, 2024, the firm has over $80B in regulatory assets under management. Insight Partners has invested in more than 800 companies worldwide and has seen over 55 portfolio companies achieve an IPO. Headquartered in New York City, Insight has offices in London, Tel Aviv, and the Bay Area. Insight’s mission is to find, fund, and work successfully with visionary executives, providing them with tailored, hands-on software expertise along their growth journey, from their first investment to IPO. For more information on Insight and all its investments, visit insightpartners.com or follow us on X @insightpartners.
Fresh inflation data released Wednesday is likely to keep the Federal Reserve on pause during its next policy meeting this month, even though a new reading did show some signs of easing.
On a “core” basis, which eliminates the more volatile costs of food and gas, the December Consumer Price Index (CPI) climbed 0.2% over the prior month, a deceleration from November’s 0.3% monthly gain. On an annual basis, prices rose 3.2%.
It was the first drop on a core basis after three months of being stuck at 3.3%.
“This latest inflation reading confirms a Fed rate cut skip at the January FOMC meeting,” said EY chief economist Gregory Daco.
The new print “won’t change expectations for a pause later this month, but it should curb some of the talk about the Fed potentially raising rates,” said Ellen Zentner, chief economic strategist for Morgan Stanley Wealth Management.
The Fed next meets on Jan. 28-29, and investors are nearly unanimous in their view the central bank will leave rates unchanged after reducing them by a full percentage point in late 2024.
“We are making progress on inflation, it’s just very slow,” former Federal Reserve economist Claudia Sahm told Yahoo Finance Wednesday. “Cuts are not coming later this month, but that doesn’t mean they aren’t coming later this year.”
Fed officials have been urging caution on rate cuts given a trend of stickier-than expected inflation data since past fall.
in fact, the Fed’s December meeting minutes showed officials believed inflation could take longer than anticipated to reach their 2% goal, citing risks from new trade and immigration policies expected from the incoming Trump administration.
They noted “the likelihood that elevated inflation could be more persistent had increased,” according to the minutes, even though they still expected the Fed to bring inflation down to its 2% goal “over the next few years.”
Several members of the Fed even said at that meeting that the disinflationary process may have stalled temporarily or noted the risk that it could.
The elevated inflation concerns help explain why Fed officials in December reduced their estimate of 2025 rate cuts to two from a previous estimate of four.
U.S. Federal Reserve Chair Jerome Powell in December. REUTERS/Kevin Lamarque ·REUTERS / Reuters
Inflation could show new signs of progress in year-over-year comparisons later in 2025’s first quarter since in 2024 inflation spiked back up before declining again.
Fed governor Michelle Bowman may be the most worried of the Fed officials, saying last week that she could have backed a pause in interest rates last month but supported a cut as the “last step” in the central bank’s “policy recalibration.”
Kansas City Fed president Jeff Schmid, a voting FOMC member this year, said “I believe we are near the point where the economy needs neither restriction nor support and that policy should be neutral.”
Schmid said he is in favor of adjusting rates “gradually,” noting that the strength of the economy allows the Fed to be patient.
Boston Fed president Susan Collins, another voting member this year, also called for a gradual approach.
“With policy already closer to a more neutral stance, I view the current nature of uncertainty as calling for a gradual and patient approach to policymaking,” Collins said.
But the new numbers out Wednesday provided a “sigh of relief” for the Fed, DWS Group head of fixed income George Catrambone.
But there is still a lot of uncertainty ahead, as new policies from the Trump administration may affect the outlook.
As to when the Fed may first cut rates in 2025, “if we don’t see it by Jackson Hole, it’s not coming,” Catrambone added, referring to an annual fed event that takes place in late August.
Wilmington, Delaware, Transparency Market Research Inc. , Jan. 15, 2025 (GLOBE NEWSWIRE) — The global metallic soap market is witnessing consistent growth, driven by increasing demand across various industries including plastics, rubber, construction, and personal care. Metallic soaps, typically composed of metallic salts like calcium, zinc, aluminum, and magnesium, are playing a critical role as lubricants, stabilizers, and release agents in a wide range of industrial applications. With the market valued at US$ 2.5 billion in 2023, it is expected to grow at a CAGR of 5.0% from 2024 to 2034, reaching US$ 4.3 billion by the end of the forecast period.
The metallic soap market is being propelled by various industries that rely on these compounds for enhancing the performance and quality of their products. The continued shift toward sustainability and the increasing focus on environmentally friendly solutions is also creating new opportunities for manufacturers to innovate and expand their market presence.
Several key players dominate the metallic soap market, leveraging their technological expertise and industry experience to maintain a competitive edge. These companies have been pivotal in shaping the current landscape, with many focusing on enhancing their product offerings and expanding their reach into emerging markets. The major players in the global metallic soap market include:
Chemtura Corporation: A leading manufacturer in the metallic soap industry, Chemtura Corporation specializes in high-performance chemicals, including metallic soaps used for stabilization and lubrication in various applications. The company’s consistent investment in research and development has positioned it as a market leader in producing advanced solutions that meet the diverse needs of customers in industries such as automotive, plastics, and personal care.
Songwon Industrial Co. Ltd.: Based in South Korea, Songwon Industrial is a significant player in the global metallic soap market. Known for its high-quality zinc stearate and other metallic soap products, Songwon serves key sectors such as plastics, rubber, and coatings. The company has built a reputation for innovation and a commitment to sustainable manufacturing practices, which has helped it strengthen its foothold in the market.
BASF SE: As a global leader in chemicals, BASF SE plays a crucial role in the metallic soap market by offering a wide range of metallic soap solutions. BASF’s products are widely used in the construction, automotive, and plastics industries. With a strong focus on sustainability and environmental stewardship, BASF is investing heavily in developing eco-friendly metallic soap alternatives to meet the growing demand for green products.
These top players are engaging in strategic collaborations, acquisitions, and expansions to strengthen their market presence and increase their product portfolio. Their continued focus on innovation, sustainability, and customer satisfaction plays a key role in shaping the future growth of the metallic soap market.
Regulatory Drivers and Innovations in the Metallic Soap Industry
• In Europe, the REACH regulation ensures metallic soaps are evaluated for safety, mandating manufacturers to comply with toxicity and environmental impact standards.
• In North America, the Toxic Substances Control Act (TSCA) regulates metallic soap use, requiring manufacturers to meet health and environmental safety standards.
• In Japan, the Chemical Substances Control Law (CSCL) enforces strict safety criteria for metallic soaps, particularly those used in personal care and construction.
• Sustainability Innovation: Manufacturers are increasingly producing biodegradable metallic soaps in response to growing eco-conscious consumer demand, especially in the paints and coatings industry.
• Biodegradable Metal Stearates: Companies are focusing on developing non-toxic, biodegradable metallic soaps like calcium and zinc stearates for use in eco-friendly applications.
Key Applications and Market Drivers
Metallic soaps are highly versatile and serve various functions, such as lubrication, thickening, waterproofing, and heat stabilization. These compounds are used in an extensive range of industries, including:
Plastics and Rubber Industry: In the plastics and rubber sectors, metallic soaps, particularly calcium, zinc, and magnesium compounds, are widely used as stabilizers, release agents, and process aids. They improve the performance of plastics and rubber products by enhancing their thermal stability, providing lubricating properties, and aiding in the processing of materials. These compounds are critical in manufacturing durable rubber products such as tires, gaskets, and seals, as well as in the production of plastics used for a variety of consumer goods.
Construction Industry: The construction industry is a major contributor to the metallic soap market. Metallic soaps are essential in the production of paints and coatings, where they act as thickeners and stabilizers. They are also used in waterproofing materials, which are in high demand as global urbanization drives the need for better infrastructure and construction techniques. The rise in the construction of residential and commercial buildings is propelling the demand for metallic soaps in various applications such as cement, adhesives, and coatings.
Personal Care and Cosmetics: The personal care industry has seen increasing adoption of metallic soaps for their emulsifying and thickening properties in cosmetics and skincare products. These soaps are used in formulations for creams, lotions, and moisturizers, contributing to the texture, stability, and shelf life of the products. As consumer demand for high-quality personal care products continues to rise, particularly in emerging markets, metallic soaps are expected to play an important role in the development of new formulations.
Paints and Coatings Industry: One of the most significant uses of metallic soaps is in the production of paints and coatings. They help to improve the flow, dispersion, and application of paints, making them ideal for both industrial and commercial uses. The global push for sustainable construction and infrastructure projects is driving demand for high-performance, eco-friendly paints, which is further contributing to the growth of the metallic soap market.
Sustainability and Innovation Driving Market Opportunities
As sustainability becomes an increasingly important factor in industrial production, the metallic soap market is undergoing significant transformation. Manufacturers are focusing on producing non-toxic, biodegradable metallic soaps that align with global environmental standards. These innovations are helping to address consumer and regulatory demands for safer, more sustainable products. The shift toward sustainability in industries such as construction, automotive, and personal care is expected to be a major factor driving the market’s growth in the coming years.
In particular, innovations in metallic soap production processes that prioritize the use of renewable resources and reduce environmental impact are creating new opportunities for market participants. Manufacturers are investing in the development of greener alternatives that can be used in a wide variety of applications, ranging from paints and coatings to personal care products.
The global metallic soap market is poised for steady growth, fueled by increasing demand across various industries and the growing emphasis on sustainability. The rise in industrial applications, particularly in plastics, rubber, construction, and personal care, provides a solid foundation for market expansion. Innovations in eco-friendly products and the growing focus on sustainability are expected to drive demand for metallic soaps in the coming years. As key industries continue to evolve, the market for metallic soaps will remain integral to the global chemicals and materials industry.
Explore Latest Research Reports by Transparency Market Research:
Isosorbide Market (Mercado de Isosorbida) – The isosorbide market is expected to witness significant growth in the future due to the rising interest for environmentally-friendly and biodegradable materials across different sectors.
Methanol-to-Olefins Market (Mercado de Metanol a Olefinas) – Global Methanol-to-Olefins industry is expected to reach a value of US$ 44.1 Bn by the end of 2034
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Financial giants have made a conspicuous bullish move on Vistra. Our analysis of options history for Vistra VST revealed 14 unusual trades.
Delving into the details, we found 35% of traders were bullish, while 35% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $90,150, and 11 were calls, valued at $694,321.
Predicted Price Range
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $110.0 to $200.0 for Vistra over the recent three months.
Analyzing Volume & Open Interest
In terms of liquidity and interest, the mean open interest for Vistra options trades today is 1315.18 with a total volume of 1,374.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Vistra’s big money trades within a strike price range of $110.0 to $200.0 over the last 30 days.
Vistra Call and Put Volume: 30-Day Overview
Significant Options Trades Detected:
Symbol
PUT/CALL
Trade Type
Sentiment
Exp. Date
Ask
Bid
Price
Strike Price
Total Trade Price
Open Interest
Volume
VST
CALL
TRADE
BEARISH
03/21/25
$10.85
$10.0
$10.0
$200.00
$200.0K
1.0K
0
VST
CALL
SWEEP
BULLISH
01/24/25
$5.0
$4.9
$5.0
$180.00
$100.3K
2.3K
10
VST
CALL
TRADE
BEARISH
01/24/25
$7.5
$7.25
$7.25
$175.00
$72.5K
236
233
VST
CALL
TRADE
BULLISH
01/17/25
$18.8
$18.8
$18.8
$155.00
$67.6K
4.7K
37
VST
CALL
SWEEP
BULLISH
01/24/25
$4.85
$4.6
$4.85
$180.00
$53.6K
2.3K
277
About Vistra
Vistra Energy is one of the largest power producers and retail energy providers in the us Following the 2024 Energy Harbor acquisition, Vistra owns 41 gigawatts of nuclear, coal, natural gas, and solar power generation along with one of the largest utility-scale battery projects in the world. Its retail electricity business serves 5 million customers in 20 states, including almost a third of all Texas electricity consumers. Vistra emerged from the Energy Future Holdings bankruptcy as a stand-alone entity in 2016. It acquired Dynegy in 2018.
After a thorough review of the options trading surrounding Vistra, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Current Position of Vistra
Trading volume stands at 309,403, with VST’s price up by 3.04%, positioned at $175.69.
RSI indicators show the stock to be may be overbought.
Earnings announcement expected in 42 days.
What Analysts Are Saying About Vistra
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $174.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge’s Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access.
* Maintaining their stance, an analyst from UBS continues to hold a Buy rating for Vistra, targeting a price of $174.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Vistra with Benzinga Pro for real-time alerts.
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 600 points on Wednesday.
Following the market opening Wednesday, the Dow traded up 1.43% to 43,130.23 while the NASDAQ rose 1.62% to 19,353.59. The S&P 500 also rose, gaining, 1.33% to 5,920.50.
Consumer discretionary shares rose by 2.2% on Tuesday.
In trading on Tuesday, health care shares fell by 0.4%.
Top Headline
The headline Consumer Price Index rose 2.9% year-over-year in December, according to Wednesday’s data from the Bureau of Labor Statistics. This marks an increase from November’s 2.7% and matches economist forecasts. Notably, it represents the third straight inflation increase and highest annual rate since July 2024.
On a monthly basis, consumer prices increased 0.4%, up from both the previous month’s 0.3% gain and the 0.3% predicted by analysts.
Equities Trading UP
Safe & Green Holdings Corp. SGBX shares shot up 176% to $1.4899. Safe & Green Holdings announced the execution of a binding Letter of Intent to acquire 100% of the outstanding securities of New Asia Holdings Inc.
Shares of Vision Marine Technologies Inc. VMARgot a boost, surging 58% to $2.21 after the company announced it filed its latest patent application with the United States Patent and Trademark Office for a Battery Authentication Encryption Technology.
Moving iMage Technologies, Inc. MITQ shares were also up, gaining 68% to $1.21.
Equities Trading DOWN
Meiwu Technology Company Limited WNW shares dropped 63% to $0.35.
Shares of Aclarion, Inc. ACON were down 62% to $0.0367 after the company reported the pricing of $14.4m public offering of common stock and warrants.
Azitra, Inc. AZTR was down, falling 40% to $0.2530 after the company announced the pricing of a $1.5 million public offering.
Commodities
In commodity news, oil traded up 1.2% to $78.41 while gold traded up 0.8% at $2,702.50.
Silver traded up 2% to $30.970 on Wednesday, while copper rose 0.7% to $4.3735.
Euro zone
European shares were higher today. The eurozone’s STOXX 600 surged 1.2%, Germany’s DAX 40 gained 1.6% and France’s CAC 40 gained 1%. Spain’s IBEX 35 Index gained 1.2%, while London’s FTSE 100 gained 0.9%.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan’s Nikkei 225 falling 0.08%, China’s Shanghai Composite Index declining 0.43%, Hong Kong’s Hang Seng Index gaining 0.34% and India’s BSE Sensex rising 0.29%.
Economics
The headline Consumer Price Index rose 2.9% year-over-year in December, according to Wednesday’s data from the Bureau of Labor Statistics.
Deep-pocketed investors have adopted a bullish approach towards Tesla TSLA, and it’s something market players shouldn’t ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in TSLA usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga’s options scanner highlighted 189 extraordinary options activities for Tesla. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 45% leaning bullish and 40% bearish. Among these notable options, 30 are puts, totaling $1,963,974, and 159 are calls, amounting to $9,808,206.
What’s The Price Target?
After evaluating the trading volumes and Open Interest, it’s evident that the major market movers are focusing on a price band between $200.0 and $700.0 for Tesla, spanning the last three months.
Insights into Volume & Open Interest
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Tesla’s options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Tesla’s significant trades, within a strike price range of $200.0 to $700.0, over the past month.
Tesla Option Activity Analysis: Last 30 Days
Largest Options Trades Observed:
Symbol
PUT/CALL
Trade Type
Sentiment
Exp. Date
Ask
Bid
Price
Strike Price
Total Trade Price
Open Interest
Volume
TSLA
CALL
TRADE
BULLISH
01/17/25
$16.5
$16.25
$16.5
$400.00
$460.3K
31.5K
2.9K
TSLA
CALL
SWEEP
NEUTRAL
01/17/25
$10.15
$9.95
$10.05
$410.00
$326.8K
15.0K
12.1K
TSLA
CALL
SWEEP
BULLISH
01/17/25
$11.2
$11.05
$11.05
$410.00
$216.7K
15.0K
9.6K
TSLA
CALL
SWEEP
BEARISH
01/17/25
$6.45
$6.3
$6.34
$420.00
$214.0K
20.8K
10.7K
TSLA
PUT
SWEEP
BULLISH
02/21/25
$26.95
$26.7
$26.7
$400.00
$203.1K
14.1K
137
About Tesla
Tesla is a vertically integrated battery electric vehicle automaker and developer of autonomous driving software. The company has multiple vehicles in its fleet, which include luxury and midsize sedans, crossover SUVs, a light truck, and a semi truck. Tesla also plans to begin selling more affordable vehicles, a sports car, and a robotaxi. Global deliveries in 2024 were a little below 1.8 million vehicles. The company sells batteries for stationary storage for residential and commercial properties including utilities and solar panels and solar roofs for energy generation. Tesla also owns a fast-charging network.
In light of the recent options history for Tesla, it’s now appropriate to focus on the company itself. We aim to explore its current performance.
Tesla’s Current Market Status
Currently trading with a volume of 4,752,458, the TSLA’s price is up by 3.17%, now at $408.91.
RSI readings suggest the stock is currently is currently neutral between overbought and oversold.
Anticipated earnings release is in 14 days.
Expert Opinions on Tesla
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $350.372.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge’s Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access.
* An analyst from GLJ Research downgraded its action to Sell with a price target of $24.
* Consistent in their evaluation, an analyst from Canaccord Genuity keeps a Buy rating on Tesla with a target price of $404.
* An analyst from Baird has decided to maintain their Outperform rating on Tesla, which currently sits at a price target of $480.
* Consistent in their evaluation, an analyst from Truist Securities keeps a Hold rating on Tesla with a target price of $351.
* An analyst from Stifel has decided to maintain their Buy rating on Tesla, which currently sits at a price target of $492.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Tesla options trades with real-time alerts from Benzinga Pro.
Austin, TX, USA, Jan. 15, 2025 (GLOBE NEWSWIRE) — Custom Market Insights has published a new research report titled “Clinical Trial Outsourcing Market Size, Trends and Insights By Services (Protocol Designing, Site Identification, Patient Recruitment, Laboratory Services, Bioanalytical Testing Services, Clinical Trial Data Management Services, Others), By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Applications (Cancer, Cardiovascular Diseases, Nervous System Diseases, Infectious Diseases, Musculoskeletal Disease, Gastroenterology Diseases, Others), By End-User (Pharmaceutical & Biopharmaceutical Companies, Medical Device Companies, Others), and By Region – Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033“ in its research database.
“According to the latest research study, the demand of global Clinical Trial Outsourcing Market size & share was valued at approximately USD 41,890 Million in 2023 and is expected to reach USD 43,102.4 Million in 2024 and is expected to reach a value of around USD 91,210.1 Million by 2033, at a compound annual growth rate (CAGR) of about 7.46% during the forecast period 2024 to 2033.”
Clinical trial outsourcing is increasing worldwide due to the growing number of clinical trials. It is a very cost-effective method for conducting clinical trials. Clinical research organisations can provide a range of services, from key capabilities to product approval and commercial launches.
Various factors, such as accelerated adoption of clinical trial outsourcing, increasing investment in drugs in the pipeline, growing investment in pharmaceutical drug innovations, rapidly expanding pharmaceutical industry in emerging economies, and increasing prevalence of chronic diseases creating burgeoning demands for new drugs, are expected to drive the clinical trial outsourcing market during the forecast period.
However, the lack of coordination between clinical trial outsourcing companies, the shortage of skilled expertise in clinical trial organisations, the growing cost of clinical trial organisations, and lengthy drug approval processes are restraining the market’s growth.
Key players operating in the market are integrating various emerging technologies, such as artificial intelligence, blockchain, machine learning, predictive analytics, advanced drug testing kits, etc., in their clinical trials to foster the speed and accuracy of clinical trials.
Machine learning-based software is integrated into many clinical trials to analyse the vast clinical requirements and patterns. Artificial intelligence-based technologies are helping to foster speed and accuracy in clinical trials, thereby boosting the drug approval processes and creating lucrative market opportunities during the forecast period.
Growing collaborations between key players involved in the clinical trial outsourcing market and biopharmaceutical companies to develop advanced and customised clinical trial technologies and equipment are expected to create lucrative market opportunities during the forecast period. For instance, many biopharmaceutical companies are collaborating with many clinical trial organisations to conduct clinical trials on a mass scale.
The global Clinical Trial Outsourcing market is segmented by services, phase, study design, application, and end users. By Services, the Laboratory Services segment dominated the global clinical trial outsourcing market and is expected to remain dominant during the forecast period. Laboratory services are the most crucial step in drug development and drug approvals.
By region, North America dominated the global Clinical Trial Outsourcing market and is expected to keep its dominance during the forecast period owing to the increasing number of clinical trials in this region coupled with growing investment in research and development activities in pharmaceutical drug development.
Various factors, such as a well-established pharmaceutical industry, increasing emphasis on new drug development due to the growing prevalence of various chronic diseases, and increasing supportive policies, are mainly driving the market growth of this region during the forecast period. Key countries, such as the U.S., Canada, and Mexico, are expected to drive the market growth of this region during the forecast period.
Report Scope
Feature of the Report
Details
Market Size in 2024
USD 43,102.4 Million
Projected Market Size in 2033
USD 91,210.1 Million
Market Size in 2023
USD 41,890 Million
CAGR Growth Rate
7.46% CAGR
Base Year
2023
Forecast Period
2024-2033
Key Segment
By Services, Phase, Study Design, Applications, End-User and Region
Report Coverage
Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America
Buying Options
Request tailored purchasing options to fulfil your research requirements.
(A free sample of the Clinical Trial Outsourcing report is available upon request; please contact us for more information.)
Our Free Sample Report Consists of the following:
Introduction, Overview, and in-depth industry analysis are all included in the 2024 updated report.
The COVID-19 Pandemic Outbreak Impact Analysis is included in the package.
About 220+ Pages Research Report (Including Recent Research)
Provide detailed chapter-by-chapter guidance on the Request.
Updated Regional Analysis with a Graphical Representation of Size, Share, and Trends for the Year 2024
Includes Tables and figures have been updated.
The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, and Revenue Analysis
Custom Market Insights (CMI) research methodology
(Please note that the sample of the Clinical Trial Outsourcing report has been modified to include the COVID-19 impact study prior to delivery.)
CMI has comprehensively analyzed the Clinical Trial Outsourcing market. The driving forces, restraints, challenges, opportunities, and key trends have been explained in depth to depict an in-depth market scenario. Segment-wise market size and market share during the forecast period have been duly addressed to portray the probable picture of this Global Clinical Trial Outsourcing industry.
The competitive landscape includes key innovators, after-market service providers, market giants, and niche players, who are studied and analyzed extensively with respect to their strengths, weaknesses, and value-adding prospects. In addition, this report covers key players’ profiles, market shares, mergers and acquisitions, consequent market fragmentation, and new trends and dynamics in partnerships.
The global Clinical Trial Outsourcing market is segmented by region into North America, Asia Pacific, Europe, Middle East & Africa, and Latin America. Of these, the North American region held the highest market share in 2023 and is expected to keep its dominance during the forecast period owing to increasing investment in drug development centres and the growing number of clinical trial organisations in the region.
Various factors, such as the presence of a well-established pharmaceutical industry, increasing investment in new drug development, rise in the adaptation of advanced technologies for drug development, and presence of leading clinical trial organisations, are some of the factors boosting the market growth of this region.
Key countries such as the U.S., Canada, and Mexico are mainly boosting the market growth of this region. For instance, according to the data published by the National Library of Medicine, in 2023, more than 20,000 clinical trials were conducted in the U.S., and this number is expected to increase rapidly due to increasing global clinical trial activities in the U.S.
The U.S. dominated the North American clinical trial outsourcing market due to supportive government policies and growing emphasis by private and government organisations on new drug development.
Asia Pacific is expected to grow at the fastest CAGR during the forecast period. Key countries such as China, India, Japan, ASEAN, South Korea and Australia are mainly driving the market growth of this region.
Various factors, such as the rapidly expanding pharmaceutical industry, the growing number of drug discovery trials, increasing investment in new drug discovery, increasing awareness about healthcare, and an increasing population coupled with growing disposable incomes, are mainly boosting the demand for new drugs and discoveries, thereby creating market opportunities for clinical trial outsourcing in this region.
China dominated the Asia Pacific Clinical Trial Outsourcing market and is expected to maintain its dominance during the forecast period owing to supportive government policies regarding clinical trial outsourcing research.
Furthermore, the increasing geriatric population, the increasing prevalence of chronic diseases, and the well-established pharmaceutical industry, coupled with the availability of well-established healthcare and pharmaceutical industries in the country, are some of the factors mainly driving the market growth of this region.
India is expected to grow at the fastest CAGR during the forecast period owing to the growing number of clinical trials in the country. In 2023, there were 74,547 clinical trials registered and ongoing in India, and this number is expected to increase in upcoming years due to increasing investment in drug discoveries.
Furthermore, various supportive policies, such as Ayushman Bharat, provide universal healthcare coverage to all Indian citizens, thereby boosting the demand for new drugs. This, in turn, encourages clinical trial outsourcing, thereby boosting market growth.
Browse the full “Clinical Trial Outsourcing Market Size, Trends and Insights By Services (Protocol Designing, Site Identification, Patient Recruitment, Laboratory Services, Bioanalytical Testing Services, Clinical Trial Data Management Services, Others), By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Applications (Cancer, Cardiovascular Diseases, Nervous System Diseases, Infectious Diseases, Musculoskeletal Disease, Gastroenterology Diseases, Others), By End-User (Pharmaceutical & Biopharmaceutical Companies, Medical Device Companies, Others), and By Region – Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033“ Report at https://www.custommarketinsights.com/report/clinical-trial-outsourcing-market/
List of the prominent players in the Clinical Trial Outsourcing Market:
US Ultrasound Probe Disinfection Market: US Ultrasound Probe Disinfection Market Size, Trends and Insights By Product (Instruments, Consumables, Services), By Disinfection Process (High-Level Disinfection, Intermediate/Low-Level Disinfection), By End-use (Hospitals & Clinics, Diagnostic Imaging Centers, Others), and By Region – Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033
UK Private Healthcare Market: UK Private Healthcare Market Size, Trends and Insights By Service Type (Primary Care, Specialty Care, Oncology, Diagnostic Services, Therapeutic Services, Emergency Care), By Facility Type (Hospitals, Private Clinics, Diagnostic Centres, Outpatient Surgery Centres, Rehabilitation Centres), and By Region – Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033
US Animal Biotechnology Market: US Animal Biotechnology Market Size, Trends and Insights By Product (Diagnostics Tests, Vaccines and Drugs, Reproductive and Genetic, Feed Additives, Others), By Application (Diagnosis of Animal Diseases, Treatment of Animal Diseases, Preventive Care of Animals, Drug Development, Others), By End User (Veterinary Laboratories, Point-of-Care Testing/In-house Testing, Veterinary Hospitals & Clinics, Others), and By Region – Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033
US Feminine Hygiene Products Market: US Feminine Hygiene Products Market Size, Trends and Insights By Product Type (Sanitary Napkins, Tampons, Menstrual Cups, Panty Liners, Feminine Hygiene Wash), By Material (Organic Cotton, Synthetic), By Application (Residential, Commercial, Healthcare, Educational Institutions), By Distribution Channel (Online, Offline), and By Region – Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033
Single Cell Multiomics Market: Single Cell Multiomics Market Size, Trends and Insights By Technology (Single-cell RNA Sequencing (scRNA-seq), Single-cell DNA Sequencing (scDNA-seq), Single-cell Proteomics, Single-cell Epigenomics, Single-cell Metabolomics, Single-cell Transcriptomics, Other), By Application (Cancer Research, Immunology, Neurology, Stem Cell Research, Developmental Biology, Drug Discovery and Development, Other), By End User (Academic and Research Institutions, Biotechnology and Pharmaceutical Companies, Clinical Research Organizations, Hospitals and Diagnostic Laboratories, Other), and By Region – Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033
Legal Cannabis Market: Legal Cannabis Market Size, Trends and Insights By Strain (THC, CBD), By Species (Cannabis Indica, Cannabis Sativa, Cannabis Hybrid), By Source (Marijuana, Hemp), By End-User (Pharmaceutical Companies, Food and Beverage Companies, Personal Care Products, Research and Development Centers), and By Region – Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033
Legal Marijuana Market: Legal Marijuana Market Size, Trends and Insights By Marijuana Type (Recreational Marijuana, Medical Marijuana), By Application (Chronic Pain, Mental Disorders, Cancer, Others (e.g., anxiety, epilepsy, PTSD)), By Product Type (Buds / Marijuana Flower, Cannabis Extracts, Oils, Tinctures, Edibles), and By Region – Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033
Silicone Implants Market: Silicone Implants Market Size, Trends and Insights By Type (Silicone Breast Implants, Silicone Facial Implants, Silicone Penile Implants, Silicone Gluteal Implants), By Application (Cosmetic Surgery, Reconstructive Surgery), By End-user (Hospitals, Specialty Clinics, Ambulatory Surgical Centers), and By Region – Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033
The Clinical Trial Outsourcing Market is segmented as follows:
This Clinical Trial Outsourcing Market Research/Analysis Report Contains Answers to the following Questions.
Which Trends Are Causing These Developments?
Who Are the Global Key Players in This Clinical Trial Outsourcing Market? What are Their Company Profile, Product Information, and Contact Information?
What Was the Global Market Status of the Clinical Trial Outsourcing Market? What Was the Capacity, Production Value, Cost and PROFIT of the Clinical Trial Outsourcing Market?
What Is the Current Market Status of the Clinical Trial Outsourcing Industry? What’s Market Competition in This Industry, Both Company and Country Wise? What’s Market Analysis of Clinical Trial Outsourcing Market by Considering Applications and Types?
What Are Projections of the Global Clinical Trial Outsourcing Industry Considering Capacity, Production and Production Value? What Will Be the Estimation of Cost and Profit? What Will Be Market Share, Supply and Consumption? What about imports and exports?
What Is Clinical Trial Outsourcing Market Chain Analysis by Upstream Raw Materials and Downstream Industry?
What Is the Economic Impact On Clinical Trial Outsourcing Industry? What are Global Macroeconomic Environment Analysis Results? What Are Global Macroeconomic Environment Development Trends?
What Are Market Dynamics of Clinical Trial Outsourcing Market? What Are Challenges and Opportunities?
What Should Be Entry Strategies, Countermeasures to Economic Impact, and Marketing Channels for Clinical Trial Outsourcing Industry?
Reasons to Purchase Clinical Trial Outsourcing Market Report
Clinical Trial Outsourcing Market Report provides qualitative and quantitative analysis of the market based on segmentation involving economic and non-economic factors.
Clinical Trial Outsourcing Market report outlines market value (USD) data for each segment and sub-segment.
This report indicates the region and segment expected to witness the fastest growth and dominate the market.
Clinical Trial Outsourcing Market Analysis by geography highlights the consumption of the product/service in the region and indicates the factors affecting the market within each region.
The competitive landscape incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled.
Extensive company profiles comprising company overview, company insights, product benchmarking, and SWOT analysis for the major market players.
The Industry’s current and future market outlook concerning recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging and developed regions.
Clinical Trial Outsourcing Market Includes in-depth market analysis from various perspectives through Porter’s five forces analysis and provides insight into the market through Value Chain.
Reasons for the Research Report
The study provides a thorough overview of the global Clinical Trial Outsourcing market. Compare your performance to that of the market as a whole.
Aim to maintain competitiveness while innovations from established key players fuel market growth.
Drivers, restrictions, and opportunities are among the qualitative elements covered in the worldwide Clinical Trial Outsourcing market analysis.
The competitive environment of current and potential participants in the Clinical Trial Outsourcing market is covered in the report, as well as those companies’ strategic product development ambitions.
According to the component, application, and industry vertical, this study analyzes the market qualitatively and quantitatively. Additionally, the report offers comparable data for the important regions.
For each segment mentioned above, actual market sizes and forecasts have been given.
Who should buy this report?
Participants and stakeholders worldwide Clinical Trial Outsourcing market should find this report useful. The research will be useful to all market participants in the Clinical Trial Outsourcing industry.
Managers in the Clinical Trial Outsourcing sector are interested in publishing up-to-date and projected data about the worldwide Clinical Trial Outsourcing market.
Governmental agencies, regulatory bodies, decision-makers, and organizations want to invest in Clinical Trial Outsourcing products’ market trends.
Market insights are sought for by analysts, researchers, educators, strategy managers, and government organizations to develop plans.
Custom Market Insights is a market research and advisory company delivering business insights and market research reports to large, small, and medium-scale enterprises. We assist clients with strategies and business policies and regularly work towards achieving sustainable growth in their respective domains.
CMI provides a one-stop solution for data collection to investment advice. The expert analysis of our company digs out essential factors that help to understand the significance and impact of market dynamics. The professional experts apply clients inside on the aspects such as strategies for future estimation fall, forecasting or opportunity to grow, and consumer survey.
On Wednesday, Goldman Sachs Group Inc.GS shares traded higher after the company reported its fourth-quarter and full-year 2024 financial results.
Goldman Sachs reported fourth-quarter revenue of $13.87 billion, beating the consensus of $12.39 billion. Revenue increased by 23% year-over-year, reflecting growth across all segments, with significant growth in Global Banking & Markets.
Full-year revenue was $53.51 billion, up 16% YoY, beating the consensus of $51.98 billion.
Net interest income for 4Q24 was $2.35 billion, 75% higher YoY, reflecting a shift towards higher-yielding assets, and was essentially unchanged QoQ. Average interest-earning assets were $1.59 trillion.
Segment Revenues: Global Banking & Markets revenues were $8.48 billion, up 33% Y/Y. This was boosted by a 24% Y/Y increase in investment banking fees to $2.05 billion, led by higher revenues in Debt and Equity underwriting. Investment banking fees backlog increased QoQ, primarily driven by Equity underwriting.
Net revenues in Fixed Income, Currency, and Commodities (FICC) were $2.74 billion, up 35% year over year, primarily reflecting higher net revenues in FICC intermediation and financing.
Net revenues from Equity grew 32% YoY to $3.45 billion, reflecting significantly higher net revenues in intermediation and financing.
Asset & Wealth Management revenue was $4.72 billion, 8% higher than last year. Total Wealth management client assets soared to ~$1.6 trillion.
Goldman Sachs clocked fourth-quarter GAAP EPS of $11.95, beating the consensus of $8.30. Full-year GAAP EPS was $40.54, beating the consensus of $36.55.
Provision for credit losses was $351 million for the fourth quarter, down 39% year over year, reflecting net provisions related to the credit card portfolio (primarily driven by net charge-offs).
In the fourth quarter, total Assets Under Supervision (AUS) saw a net inflow of $92 billion. Total AUS for 2024 increased by $325 billion to a record $3.14 trillion.
Stock Buyback: In the fourth quarter, Goldman Sachs repurchased stock worth $2 billion, bringing the yearly stock buyback to $8 billion.
The Standardized CET capital ratio increased to 15%, and the Advanced CET capital ratio increased to 15.4%. The book value per common share increased to $336.77 YoY, compared to $313.56.
In the last 12 months, Goldman Sachs stock has gained 50%, outperforming the S&P500 and the Dow by a huge margin.
Analyst Ratings: In the last 15 days, Oppenheimer lowered Goldman Sachs stock price forecast from $677 to $639, UBS downgraded the stock to a Neutral rating with a price forecast of $610, and Barclays raised the price forecast from $588 to $713.
Investors can gain exposure to the Goldman Sachs stock via Shares U.S. Broker-Dealers & Securities Exchanges ETFIAI, SPDR Dow Jones Industrial Average ETF Trust (NYSE:DIA), and Invesco KBW Bank ETFKBWB.
Price Action: GS shares are up 2.54% at $586.05 premarket at the last check on Wednesday.
View original content to download multimedia:
